Genexine Co. Ltd.
32 articles about Genexine Co. Ltd.
-
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
10/23/2023
Genexine together with PT Kalbe Genexine Biologics, a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its long-acting erythropoietin, Efepoetin alfa, by the Indonesian Ministry of Food and Drug Safety for the treatment of chronic kidney disease induced anemia in non-dialysis patients.
-
Genexine’s long-acting growth hormone meets Phase 3 primary endpoint
8/30/2023
Genexine (KOSDAQ:095700, CEO Neil Warma) today announced positive topline results from the multi-center, randomized, open-label, active-controlled pivotal phase 3 study (CTJ101PGHD301) being conducted in China to evaluate the efficacy and safety of eftansomatropin alfa (Genexine’s proprietary long-acting growth hormone, also known as GX-H9) in children with growth hormone deficiency.
-
Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting
5/26/2023
Genexine announced the publication of an abstract of its phase 2 clinical trial on triple combination neoadjuvant therapy for HNSCC in the ASCO.
-
Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera
4/11/2023
A clinical-staged proprietary platform technology biotech company Genexine and its Asian regional partner, KG Bio unveiled the interim results of phase 3 clinical trial of GX-E4, a candidate for CKD induced anemia.
-
Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer
1/20/2023
Genexine (KOSDAQ: 095700) today announced it received Fast Track Designation (FTD) from the Korean Ministry of Food and Drug Safety (MFDS) for GX-188E (tirvalimogene teraplasmid), its first-in-class proprietary therapeutic DNA vaccine.
-
Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference
1/9/2023
Genexine announced updated results following the completion of its Phase 2 clinical study using GX-188E, its first-in-class proprietary DNA vaccine, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy.
-
Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer
9/7/2022
Genexine (KOSDAQ: 095700), today announced that GX-188E, its first-in-class proprietary DNA vaccine, demonstrated potent efficacy and favorable safety in patients with advanced cervical cancer in a phase 2 study when given in combination with KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy.
-
Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022
8/25/2022
Genexine, announced that late-breaking results from the Phase 2 clinical trial study of its therapeutic DNA vaccine GX-188E in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, were selected for an oral presentation at the 2022 European Society for Medical Oncology Congress which is being held from September 9-13 in Paris, France.
-
Novartis' canakinumab failed again in non-small cell lung cancer while Anixa Biosciences, Palisade Bio and Genexine kicked off new trials.
-
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
8/17/2022
Genexine announced the dosing of the first patient in phase 2 clinical trial using triple combination therapy in patients with recurrent/metastatic HNSCC.
-
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)
6/14/2022
Genexine announced that its partner, I-Mab, recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, also known as GX-H9/TJ101, in China, taking it one step closer to commercialization in a key market.
-
Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer
6/7/2022
Genexine announced top-line results from the KEYNOTE-899 phase 1b/2 clinical trial of GX-I7 in combination with pembrolizumab.
-
Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation
5/25/2022
Genexine a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the appointment of Neil Warma as its President and Chief Executive Officer.
-
Genexine to Present at H.C. Wainwright Global Investment Conference
5/25/2022
Genexine announced that Neil Warma, CEO of Genexine will be presenting virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
-
Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-negative Breast Cancer
11/10/2020
Genexine, Inc. and NeoImmuneTech, Inc. announced the release of data for the dose escalation phase of their Ph1b/2 study of GX-I7/NT-I7, a novel T cell amplifier, in combination with KEYTRUDA®, a leading checkpoint inhibitor, for the treatment of heavily pretreated patients with relapsed or refractory triple-negative breast cancer.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
-
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme
5/21/2020
- I-Mab to initiate Phase 2 clinical trial in glioblastoma multiforme (GBM) in China - I-Mab and Genexine expand collaboration for development of TJ107/HyLeukin-7™
-
Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer
4/26/2019
Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7™, their T cell amplifier, in combination with Merck’s anti PD-1 therapy, KEYTRUDA
-
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy
11/2/2018
A Potential Global First-in-Class Long-Acting IL-7 for Chemotherapy induced Lymphopenia and Cancer Immunotherapy
-
Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA®
7/18/2018
Genexine will conduct a phase 1b/2 clinical trial to investigate the safety and efficacy of Hyleukin-7 treatment in combination with Merck’s anti PD-1 therapy, KEYTRUDA® in patients with triple-negative breast cancer.